About
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry.
The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile.
The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal.
Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.
Coventry